Stocks News

LAST PRICE
206.3300
TODAY'S CHANGE (%)
Trending Down-3.0100 (-1.4379%)

Bid / Lots
173.2900/ 1
Ask / Lots
229.9300/ 1
Open / Previous Close
209.1000 / 209.3400
Day Range
Low 205.0000
High 210.9400
52 Week Range
Low 132.2400
High 229.9700
Volume
2,928,056
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 23, 2024
- ResMed Says Research Shows Effectiveness of Positive Airway Pressure Therapy For Sleep Apnea, from 10:37AM ET on Thursday May 23, 2024 by MT Newswires
  10:37AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: RMD
  10:37 AM EDT, 05/23/2024 (MT Newswires) -- ResMed (RMD) said Thursday new findings showed that positive airway pressure therapy decreased risks of death and hospitalization for people with obstructive sleep apnea. ResMed said several studies support...
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy, from 9:05AM ET on Thursday May 23, 2024 by GlobeNewswire
  9:05AM ET on Thursday May 23, 2024 by GlobeNewswire
  Companies Mentioned: RMD
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy, from 9:05AM ET on Thursday May 23, 2024 by Dow Jones
  9:05AM ET on Thursday May 23, 2024 by Dow Jones
  Companies Mentioned: RMD
  
  Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
May 16, 2024
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy, from 4:35PM ET on Thursday May 16, 2024 by GlobeNewswire
  4:35PM ET on Thursday May 16, 2024 by GlobeNewswire
  Companies Mentioned: RMD
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy, from 4:35PM ET on Thursday May 16, 2024 by Dow Jones
  4:35PM ET on Thursday May 16, 2024 by Dow Jones
  Companies Mentioned: RMD
  
  ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
  
  SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) --

Yesterday
- Stifel Nicolaus Adjusts Veeva Systems Price Target to $210 From $250, Maintains Buy Rating, from 11:26AM ET on Friday May 31, 2024 by MT Newswires
  11:26AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
- Evercore ISI Cuts Price Target on Veeva Systems to $200 From $230, Maintains In-Line Rating, from 10:33AM ET on Friday May 31, 2024 by MT Newswires
  10:33AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
- UBS Adjusts Veeva Systems Price Target to $185 From $235, Maintains Neutral Rating, from 9:52AM ET on Friday May 31, 2024 by MT Newswires
  9:52AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
- Baird Adjusts Veeva Systems' Price Target to $245 From $255, Maintains Outperform Rating, from 9:47AM ET on Friday May 31, 2024 by MT Newswires
  9:47AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
- Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday, from 9:19AM ET on Friday May 31, 2024 by MT Newswires
  9:19AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: IBB, XLV, ABBV, VEEV, SMMT
- Piper Sandler Cuts Price Target on Veeva Systems to $235 From $245, Maintains Overweight Rating, from 8:47AM ET on Friday May 31, 2024 by MT Newswires
  8:47AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
- Morgan Stanley Cuts Price Target on Veeva Systems to $173 From $210, Says Billings 'Continue to Disappoint,' Keeps Underweight Rating, from 7:00AM ET on Friday May 31, 2024 by MT Newswires
  7:00AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
- Update: Veeva Systems Fiscal Q1 Non-GAAP Earnings, Sales Rise But Full-Year Revenue Guidance Cut; Shares Fall Premarket, from 5:30AM ET on Friday May 31, 2024 by MT Newswires
  5:30AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: VEEV
May 30, 2024
- Veeva Systems Fiscal Q1 Non-GAAP EPS, Revenue Rise; FY 2025 Revenue Guidance Cut; Shares Fall After Hour, from 5:18PM ET on Thursday May 30, 2024 by MT Newswires
  5:18PM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: VEEV
- -- Earnings Flash (VEEV) VEEVA SYSTEMS Reports Q1 EPS $1.50, vs. Street Est of $1.43, from 4:41PM ET on Thursday May 30, 2024 by MT Newswires
  4:41PM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: VEEV

Resmed Inc
NYSE:RMDUnited States

Search Criteria

May 23, 2024

ResMed Says Research Shows Effectiveness of Positive Airway Pressure Therapy For Sleep Apnea, from 10:37AM ET on Thursday May 23, 2024 by MT Newswires

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy, from 9:05AM ET on Thursday May 23, 2024 by GlobeNewswire

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy, from 9:05AM ET on Thursday May 23, 2024 by Dow Jones

May 16, 2024

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy, from 4:35PM ET on Thursday May 16, 2024 by GlobeNewswire

ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy, from 4:35PM ET on Thursday May 16, 2024 by Dow Jones

Peers Headlines

Yesterday

Stifel Nicolaus Adjusts Veeva Systems Price Target to $210 From $250, Maintains Buy Rating, from 11:26AM ET on Friday May 31, 2024 by MT Newswires

Evercore ISI Cuts Price Target on Veeva Systems to $200 From $230, Maintains In-Line Rating, from 10:33AM ET on Friday May 31, 2024 by MT Newswires

UBS Adjusts Veeva Systems Price Target to $185 From $235, Maintains Neutral Rating, from 9:52AM ET on Friday May 31, 2024 by MT Newswires

Baird Adjusts Veeva Systems' Price Target to $245 From $255, Maintains Outperform Rating, from 9:47AM ET on Friday May 31, 2024 by MT Newswires

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday, from 9:19AM ET on Friday May 31, 2024 by MT Newswires

Piper Sandler Cuts Price Target on Veeva Systems to $235 From $245, Maintains Overweight Rating, from 8:47AM ET on Friday May 31, 2024 by MT Newswires

Morgan Stanley Cuts Price Target on Veeva Systems to $173 From $210, Says Billings 'Continue to Disappoint,' Keeps Underweight Rating, from 7:00AM ET on Friday May 31, 2024 by MT Newswires

Update: Veeva Systems Fiscal Q1 Non-GAAP Earnings, Sales Rise But Full-Year Revenue Guidance Cut; Shares Fall Premarket, from 5:30AM ET on Friday May 31, 2024 by MT Newswires

May 30, 2024

Veeva Systems Fiscal Q1 Non-GAAP EPS, Revenue Rise; FY 2025 Revenue Guidance Cut; Shares Fall After Hour, from 5:18PM ET on Thursday May 30, 2024 by MT Newswires

-- Earnings Flash (VEEV) VEEVA SYSTEMS Reports Q1 EPS $1.50, vs. Street Est of $1.43, from 4:41PM ET on Thursday May 30, 2024 by MT Newswires